Journal of Neuroimmune Pharmacology

, Volume 7, Issue 4, pp 951–968 | Cite as

Persistent Neuroinflammatory Effects of Serial Exposure to Stress and Methamphetamine on the Blood-Brain Barrier

  • Nicole A. Northrop
  • Bryan K. YamamotoEmail author


Studies of methamphetamine (Meth)-induced neurotoxicity have traditionally focused on monoaminergic terminal damage while more recent studies have found that stress exacerbates these damaging effects of Meth. Similarities that exist between the mechanisms that cause monoaminergic terminal damage in response to stress and Meth and those capable of producing a disruption of the blood-brain barrier (BBB) suggest that the well-known high co-morbidity of stress and Meth could produce long-lasting structural and functional BBB disruption. The current studies examined the role of neuroinflammation in mediating the effects of exposure to chronic stress and/or Meth on BBB structure and function. Rats were pre-exposed to chronic unpredictable stress (CUS) and/or challenged with Meth. Twenty-four hours after the treatment of Meth in rats pre-exposed to CUS, occludin and claudin-5 immunoreactivity were decreased while truncation of β-dystroglycan, as well as FITC-dextran and water extravasation was increased. All changes other than β-dystroglycan and edema persisted 7 days later, occurred with increases in GFAP and COX-2, and were blocked by ketoprofen after Meth treatment. In addition, persistent increases in FITC-dextran extravasation were prevented by treatment with an EP1 receptor antagonist after Meth exposure. The results indicate that CUS and Meth synergize to produce long-lasting structural and functional BBB disruptions that are mediated by cyclooxygenase and protracted increases in inflammation. These results suggest that stress and Meth can synergize to produce a long-lasting vulnerability of the brain to subsequent environmental insults resulting from the persistent breach of the BBB.


Methamphetamine Stress Blood-brain barrier Cyclooxygenase Neuroinflammation 



This work was supported by the National Institute of Health Grant DA07606. We would like to thank Dr. Andrea Nestor-Kalinoski for her technical assistance with the confocal imaging of FITC-dextran extravasation and Gattefossé Corporation for their generosity in supplying us with transcutol for our experiments.

Conflict of interest

The authors declare that they have no conflict of interest.


  1. Abbott NJ (2000) Inflammatory mediators and modulation of blood-brain barrier permeability. Cell Mol Neurobiol 20:131–147PubMedCrossRefGoogle Scholar
  2. Abdul Muneer PM, Alikunju S, Szlachetka AM, Murrin LC, Haorah J (2011) Impairment of brain endothelial glucose transporter by methamphetamine causes blood-brain barrier dysfunction. Mol Neurodegener 6:23PubMedCrossRefGoogle Scholar
  3. Aid S, Silva AC, Candelario-Jalil E, Choi SH, Rosenberg GA, Bosetti F (2010) Cyclooxygenase-1 and -2 differentially modulate lipopolysaccharide-induced blood-brain barrier disruption through matrix metalloproteinase activity. J Cereb Blood Flow Metab 30:370–380PubMedCrossRefGoogle Scholar
  4. Asanuma M, Tsuji T, Miyazaki I, Miyoshi K, Ogawa N (2003) Methamphetamine-induced neurotoxicity in mouse brain is attenuated by ketoprofen, a non-steroidal anti-inflammatory drug. Neurosci Lett 352:13–16PubMedCrossRefGoogle Scholar
  5. Barichello T, Lemos JC, Generoso JS, Cipriano AL, Milioli GL, Marcelino DM, Vuolo F, Petronilho F, Dal-Pizzol F, Vilela MC, Teixeira AL (2011) Oxidative stress, cytokine/chemokine and disruption of blood–brain barrier in neonate rats after meningitis by streptococcus agalactiae. Neurochem ResGoogle Scholar
  6. Bos CL, Richel DJ, Ritsema T, Peppelenbosch MP, Versteeg HH (2004) Prostanoids and prostanoid receptors in signal transduction. Int J Biochem Cell Biol 36:1187–1205PubMedCrossRefGoogle Scholar
  7. Bowyer JF, Ali S (2006) High doses of methamphetamine that cause disruption of the blood–brain barrier in limbic regions produce extensive neuronal degeneration in mouse hippocampus. Synapse 60:521–532PubMedCrossRefGoogle Scholar
  8. Candelario-Jalil E, Taheri S, Yang Y, Sood R, Grossetete M, Estrada EY, Fiebich BL, Rosenberg GA (2007) Cyclooxygenase inhibition limits blood–brain barrier disruption following intracerebral injection of tumor necrosis factor-alpha in the rat. J Pharmacol Exp Ther 323:488–498PubMedCrossRefGoogle Scholar
  9. Chapman DE, Hanson GR, Kesner RP, Keefe KA (2001) Long-term changes in basal ganglia function after a neurotoxic regimen of methamphetamine. J Pharmacol Exp Ther 296:520–527PubMedGoogle Scholar
  10. Cruickshank CC, Dyer KR (2009) A review of the clinical pharmacology of methamphetamine. Addiction 104:1085–1099PubMedCrossRefGoogle Scholar
  11. Dehouck MP, Meresse S, Delorme P, Fruchart JC, Cecchelli R (1990) An easier, reproducible, and mass-production method to study the blood–brain barrier in vitro. J Neurochem 54:1798–1801PubMedCrossRefGoogle Scholar
  12. Ernst T, Chang L, Leonido-Yee M, Speck O (2000) Evidence for long-term neurotoxicity associated with methamphetamine abuse: A 1H MRS study. Neurology 54:1344–1349PubMedCrossRefGoogle Scholar
  13. Eyerman DJ, Yamamoto BK (2007) A rapid oxidation and persistent decrease in the vesicular monoamine transporter 2 after methamphetamine. J Neurochem 103:1219–1227PubMedCrossRefGoogle Scholar
  14. Flora G, Lee YW, Nath A, Maragos W, Hennig B, Toborek M (2002) Methamphetamine-induced TNF-alpha gene expression and activation of AP-1 in discrete regions of mouse brain: potential role of reactive oxygen intermediates and lipid peroxidation. Neuromolecular Med 2:71–85PubMedCrossRefGoogle Scholar
  15. Foster RT, Jamali F (1988) Stereoselective pharmacokinetics of ketoprofen in the rat. Influence of route of administration. Drug Metabol Dispos 16:623–626Google Scholar
  16. Fukumoto K, Takagi N, Yamamoto R, Moriyama Y, Takeo S, Tanonaka K (2010) Prostanoid EP1 receptor antagonist reduces blood-brain barrier leakage after cerebral ischemia. Eur J Pharmacol 640:82–86PubMedCrossRefGoogle Scholar
  17. Garcia-Bueno B, Caso JR, Leza JC (2008) Stress as a neuroinflammatory condition in brain: damaging and protective mechanisms. Neurosci Biobehav Rev 32:1136–1151PubMedCrossRefGoogle Scholar
  18. Haile CN, GrandPre T, Kosten TA (2001) Chronic unpredictable stress, but not chronic predictable stress, enhances the sensitivity to the behavioral effects of cocaine in rats. Psychopharmacology 154:213–220PubMedCrossRefGoogle Scholar
  19. Hawkins BT, Abbruscato TJ, Egleton RD, Brown RC, Huber JD, Campos CR, Davis TP (2004) Nicotine increases in vivo blood-brain barrier permeability and alters cerebral microvascular tight junction protein distribution. Brain Res 1027:48–58PubMedCrossRefGoogle Scholar
  20. Hirsch EC, Breidert T, Rousselet E, Hunot S, Hartmann A, Michel PP (2003) The role of glial reaction and inflammation in Parkinson’s disease. Ann N Y Acad Sci 991:214–228PubMedCrossRefGoogle Scholar
  21. Hotchkiss AJ, Gibb JW (1980) Long-term effects of multiple doses of methamphetamine on tryptophan hydroxylase and tyrosine hydroxylase activity in rat brain. J Pharmacol Exp Ther 214:257–262PubMedGoogle Scholar
  22. Johnson BN, Yamamoto BK (2009) Chronic unpredictable stress augments +3,4-methylenedioxymethamphetamine-induced monoamine depletions: the role of corticosterone. Neuroscience 159:1233–1243PubMedCrossRefGoogle Scholar
  23. Johnson JD, O’Connor KA, Deak T, Stark M, Watkins LR, Maier SF (2002) Prior stressor exposure sensitizes LPS-induced cytokine production. Brain Behav Immun 16:461–476PubMedCrossRefGoogle Scholar
  24. Kawano T, Anrather J, Zhou P, Park L, Wang G, Frys KA, Kunz A, Cho S, Orio M, Iadecola C (2006) Prostaglandin E2 EP1 receptors: downstream effectors of COX-2 neurotoxicity. Nat Med 12:225–229PubMedCrossRefGoogle Scholar
  25. Kita T, Shimada K, Mastunari Y, Wagner GC, Kubo K, Nakashima T (2000) Methamphetamine-induced striatal dopamine neurotoxicity and cyclooxygenase-2 protein expression in BALB/c mice. Neuropharmacology 39:399–406PubMedCrossRefGoogle Scholar
  26. Kiyatkin EA, Sharma HS (2009a) Permeability of the blood-brain barrier depends on brain temperature. Neuroscience 161:926–939PubMedCrossRefGoogle Scholar
  27. Kiyatkin EA, Sharma HS (2009b) Acute methamphetamine intoxication brain hyperthermia, blood-brain barrier, brain edema, and morphological cell abnormalities. Int Rev Neurobiol 88:65–100PubMedCrossRefGoogle Scholar
  28. Kiyatkin EA, Brown PL, Sharma HS (2007) Brain edema and breakdown of the blood-brain barrier during methamphetamine intoxication: critical role of brain hyperthermia. Eur J Neurosci 26:1242–1253PubMedCrossRefGoogle Scholar
  29. Kousik SM, Graves SM, Napier TC, Zhao C, Carvey PM (2011) Methamphetamine-induced vascular changes lead to striatal hypoxia and dopamine reduction. Neuroreport 22:923–928PubMedCrossRefGoogle Scholar
  30. Lee YW, Hennig B, Yao J, Toborek M (2001) Methamphetamine induces AP-1 and NF-kappaB binding and transactivation in human brain endothelial cells. J Neurosci Res 66:583–591PubMedCrossRefGoogle Scholar
  31. Loftis JM, Choi D, Hoffman W, Huckans MS (2011) Methamphetamine causes persistent immune dysregulation: a cross-species, translational report. Neurotox Res 20:59–68PubMedCrossRefGoogle Scholar
  32. Madrigal JL, Olivenza R, Moro MA, Lizasoain I, Lorenzo P, Rodrigo J, Leza JC (2001) Glutathione depletion, lipid peroxidation and mitochondrial dysfunction are induced by chronic stress in rat brain. Neuropsychopharmacology 24:420–429PubMedCrossRefGoogle Scholar
  33. Madrigal JL, Moro MA, Lizasoain I, Lorenzo P, Fernandez AP, Rodrigo J, Bosca L, Leza JC (2003) Induction of cyclooxygenase-2 accounts for restraint stress-induced oxidative status in rat brain. Neuropsychopharmacology 28:1579–1588PubMedCrossRefGoogle Scholar
  34. Martins T, Baptista S, Goncalves J, Leal E, Milhazes N, Borges F, Ribeiro CF, Quintela O, Lendoiro E, Lopez-Rivadulla M, Ambrosio AF, Silva AP (2011) Methamphetamine transiently increases the blood-brain barrier permeability in the hippocampus: role of tight junction proteins and matrix metalloproteinase-9. Brain Res 1411:28–40PubMedGoogle Scholar
  35. Matuszewich L, Yamamoto BK (2004) Chronic stress augments the long-term and acute effects of methamphetamine. Neuroscience 124:637–646PubMedCrossRefGoogle Scholar
  36. McCann UD, Wong DF, Yokoi F, Villemagne V, Dannals RF, Ricaurte GA (1998) Reduced striatal dopamine transporter density in abstinent methamphetamine and methcathinone users: evidence from positron emission tomography studies with [11C]WIN-35,428. J Neurosci 18:8417–8422PubMedGoogle Scholar
  37. McKetin R, Kelly E, McLaren J (2006) The relationship between crystalline methamphetamine use and methamphetamine dependence. Drug Alcohol Depend 85:198–204PubMedCrossRefGoogle Scholar
  38. Michaluk P, Kolodziej L, Mioduszewska B, Wilczynski GM, Dzwonek J, Jaworski J, Gorecki DC, Ottersen OP, Kaczmarek L (2007) Beta-dystroglycan as a target for MMP-9, in response to enhanced neuronal activity. J Biol Chem 282:16036–16041PubMedCrossRefGoogle Scholar
  39. Mohammadi MT, Shid Moosavi SM, Dehghani GA (2011) Contribution of Nitric Oxide Synthase (NOS) activity in blood–brain barrier disruption and edema after acute ischemia/reperfusion in aortic coarctation-induced hypertensive rats. Iran Biomed J 15:22–30PubMedGoogle Scholar
  40. Nair A, Bonneau RH (2006) Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation. J Neuroimmunol 171:72–85PubMedCrossRefGoogle Scholar
  41. Nitta T, Hata M, Gotoh S, Seo Y, Sasaki H, Hashimoto N, Furuse M, Tsukita S (2003) Size-selective loosening of the blood–brain barrier in claudin-5-deficient mice. J Cell Biol 161:653–660PubMedCrossRefGoogle Scholar
  42. Papadopoulos MC, Manley GT, Krishna S, Verkman AS (2004) Aquaporin-4 facilitates reabsorption of excess fluid in vasogenic brain edema. FASEB J 18:1291–1293PubMedGoogle Scholar
  43. Park M, Hennig B, Toborek M (2012) Methamphetamine alters occludin expression via NADPH oxidase-induced oxidative insult and intact caveolae. J Cell Mol Med 16:362–375PubMedCrossRefGoogle Scholar
  44. Perry VH (2007) Stress primes microglia to the presence of systemic inflammation: implications for environmental influences on the brain. Brain Behav Immun 21:45–46PubMedCrossRefGoogle Scholar
  45. Quaegebeur A, Lange C, Carmeliet P (2011) The neurovascular link in health and disease: molecular mechanisms and therapeutic implications. Neuron 71:406–424PubMedCrossRefGoogle Scholar
  46. Ramirez SH, Potula R, Fan S, Eidem T, Papugani A, Reichenbach N, Dykstra H, Weksler BB, Romero IA, Couraud PO, Persidsky Y (2009) Methamphetamine disrupts blood–brain barrier function by induction of oxidative stress in brain endothelial cells. J Cereb Blood Flow Metab 29:1933–1945PubMedCrossRefGoogle Scholar
  47. Ricaurte GA, Schuster CR, Seiden LS (1980) Long-term effects of repeated methylamphetamine administration on dopamine and serotonin neurons in the rat brain: a regional study. Brain Res 193:153–163PubMedCrossRefGoogle Scholar
  48. Stein-Behrens B, Mattson MP, Chang I, Yeh M, Sapolsky R (1994) Stress exacerbates neuron loss and cytoskeletal pathology in the hippocampus. J Neurosci 14:5373–5380PubMedGoogle Scholar
  49. Tata DA, Yamamoto BK (2007) Interactions between methamphetamine and environmental stress: role of oxidative stress, glutamate and mitochondrial dysfunction. Addiction 102(Suppl 1):49–60PubMedCrossRefGoogle Scholar
  50. Tata DA, Raudensky J, Yamamoto BK (2007) Augmentation of methamphetamine-induced toxicity in the rat striatum by unpredictable stress: contribution of enhanced hyperthermia. Eur J Neurosci 26:739–748PubMedCrossRefGoogle Scholar
  51. Thomas DM, Kuhn DM (2005) Cyclooxygenase-2 is an obligatory factor in methamphetamine-induced neurotoxicity. J Pharmacol Exp Ther 313:870–876PubMedCrossRefGoogle Scholar
  52. Thomas DM, Walker PD, Benjamins JA, Geddes TJ, Kuhn DM (2004) Methamphetamine neurotoxicity in dopamine nerve endings of the striatum is associated with microglial activation. J Pharmacol Exp Ther 311:1–7PubMedCrossRefGoogle Scholar
  53. Verkhratsky A, Olabarria M, Noristani HN, Yeh CY, Rodriguez JJ (2010) Astrocytes in Alzheimer’s disease. Neurotherapeutics 7:399–412PubMedCrossRefGoogle Scholar
  54. Volkow ND, Chang L, Wang GJ, Fowler JS, Franceschi D, Sedler M, Gatley SJ, Miller E, Hitzemann R, Ding YS, Logan J (2001a) Loss of dopamine transporters in methamphetamine abusers recovers with protracted abstinence. J Neurosci 21:9414–9418PubMedGoogle Scholar
  55. Volkow ND, Chang L, Wang GJ, Fowler JS, Leonido-Yee M, Franceschi D, Sedler MJ, Gatley SJ, Hitzemann R, Ding YS, Logan J, Wong C, Miller EN (2001b) Association of dopamine transporter reduction with psychomotor impairment in methamphetamine abusers. Am J Psychiatry 158:377–382PubMedCrossRefGoogle Scholar
  56. Wagner GC, Ricaurte GA, Seiden LS, Schuster CR, Miller RJ, Westley J (1980) Long-lasting depletions of striatal dopamine and loss of dopamine uptake sites following repeated administration of methamphetamine. Brain Res 181:151–160PubMedCrossRefGoogle Scholar
  57. Wolburg-Buchholz K, Mack AF, Steiner E, Pfeiffer F, Engelhardt B, Wolburg H (2009) Loss of astrocyte polarity marks blood–brain barrier impairment during experimental autoimmune encephalomyelitis. Acta Neuropathol 118:219–233PubMedCrossRefGoogle Scholar
  58. Yamagata K, Andreasson KI, Kaufmann WE, Barnes CA, Worley PF (1993) Expression of a mitogen-inducible cyclooxygenase in brain neurons: regulation by synaptic activity and glucocorticoids. Neuron 11:371–386PubMedCrossRefGoogle Scholar
  59. Yamamoto BK, Zhu W (1998) The effects of methamphetamine on the production of free radicals and oxidative stress. J Pharmacol Exp Ther 287:107–114PubMedGoogle Scholar
  60. Yamamoto M, Ramirez SH, Sato S, Kiyota T, Cerny RL, Kaibuchi K, Persidsky Y, Ikezu T (2008) Phosphorylation of claudin-5 and occludin by rho kinase in brain endothelial cells. Am J Pathol 172:521–533PubMedCrossRefGoogle Scholar
  61. Yamamoto BK, Moszczynska A, Gudelsky GA (2010) Amphetamine toxicities: classical and emerging mechanisms. Ann N Y Acad Sci 1187:101–121PubMedCrossRefGoogle Scholar
  62. Yang GY, Gong C, Qin Z, Liu XH, Lorris Betz A (1999) Tumor necrosis factor alpha expression produces increased blood–brain barrier permeability following temporary focal cerebral ischemia in mice. Brain Res Mol Brain Res 69:135–143PubMedCrossRefGoogle Scholar
  63. Yousif S, Marie-Claire C, Roux F, Scherrmann JM, Decleves X (2007) Expression of drug transporters at the blood–brain barrier using an optimized isolated rat brain microvessel strategy. Brain Res 1134:1–11PubMedCrossRefGoogle Scholar
  64. Zhao C, Ling Z, Newman MB, Bhatia A, Carvey PM (2007) TNF-alpha knockout and minocycline treatment attenuates blood–brain barrier leakage in MPTP-treated mice. Neurobiol Dis 26:36–46PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2012

Authors and Affiliations

  1. 1.Department of NeurosciencesUniversity of Toledo College of Medicine, Health Sciences CampusToledoUSA

Personalised recommendations